Selected serum cytokines and vitamin D levels as potential prognostic markers of acute ischemic stroke.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Vitamin D*/blood ; Ischemic Stroke*/blood ; Ischemic Stroke*/diagnosis ; Biomarkers*/blood ; Cytokines*/blood; Humans ; Female ; Male ; Prognosis ; Middle Aged ; Aged ; Interleukin-4/blood ; Interferon-gamma/blood ; Case-Control Studies

Inflammation-derived oxidative stress is postulated to contribute to neuronal damage leading to poor clinical outcomes in Acute Ischemic Stroke (AIS). We aimed to investigate the association between serum levels of selected cytokines (IL-1β, IFN-γ, IL-4), and vitamin D in ischemic stroke progression, and their accuracy in predicting AIS prognosis, among Sri Lankans. We compared 60 AIS patients admitted in 4 phases post-stroke onset (<6 h; 6-24 h; 24-48 h; 48-96 h; n = 15/phase), with 15 age- and sex-matched controls. The 30-day functional outcome (FO) was assessed using the modified Rankin Scale (mRS). Serum cytokine and vitamin D levels were quantified using sandwich ELISAs, and competitive ELISA, respectively. The CombiROC web tool established optimal prognostic biomarker combinations. Serum IL-1β and IFN-γ were elevated in all four phases following stroke onset while IL-4 was elevated exclusively in the recovery phase (48-96 h) (p<0.05). Th1 bias polarization of the Th1:Th2 cytokine (IFN-γ:IL-4) ratio occurred with AIS progression while a Th2 bias occurred during AIS recovery (p<0.05). Lower serum IL-1β and higher IL-4 levels were associated with a good FO (p<0.05), while lower Vitamin D levels were related to a poor FO (p = 0.001). The triple-biomarker panel, IL-4- IFN-γ -Vit D, accurately predicted AIS prognosis (sensitivity = 100%, specificity = 91.9%, area under the curve = 0.98). Serum immunologic mediators IFN-γ, IL-4, and vitamin D may be useful biomarkers of AIS prognosis and may serve as therapeutic targets in improving stroke outcomes. Vitamin D supplementation may improve the prognosis of AIS patients. Furthermore, binary logistic model fitted for FO indicated Th1:Th2 cytokine ratio (IFN-γ:IL-4), vitamin D status, history of stroke, and ischemic heart disease as significant predictors of AIS prognosis.
Competing Interests: The authors declare that no competing interests exist.
(Copyright: © 2024 Samarakoon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Stroke. 2017 Jul;48(7):1818-1826. (PMID: 28526765)
Psychooncology. 2018 Aug;27(8):2056-2059. (PMID: 29808508)
Cell Transplant. 2016;25(8):1473-88. (PMID: 26996530)
Lancet. 2016 Aug 20;388(10046):787-96. (PMID: 27497862)
JBMR Plus. 2020 Oct 18;5(1):e10419. (PMID: 33553986)
Nutrients. 2022 Jul 04;14(13):. (PMID: 35807941)
Int J Neurosci. 2019 Jan;129(1):49-54. (PMID: 30033803)
Neurobiol Dis. 2011 Mar;41(3):717-24. (PMID: 21168500)
Galen Med J. 2021 Jun 05;10:e2097. (PMID: 35572849)
Acta Pharm Sin B. 2020 Sep;10(9):1634-1645. (PMID: 33088684)
Antioxidants (Basel). 2020 Apr 17;9(4):. (PMID: 32316584)
Genes Immun. 1999 Sep;1(1):3-19. (PMID: 11197303)
J Neuroinflammation. 2019 Jul 10;16(1):142. (PMID: 31291966)
Biochem Soc Trans. 2007 Nov;35(Pt 5):1122-6. (PMID: 17956293)
Front Horm Res. 2018;50:14-30. (PMID: 29597233)
J Neuroinflammation. 2019 Jun 7;16(1):121. (PMID: 31174550)
Stroke. 1999 Oct;30(10):2174-9. (PMID: 10512924)
Sci Rep. 2017 Mar 30;7:45477. (PMID: 28358118)
Int J Med Sci. 2021 Sep 9;18(16):3644-3651. (PMID: 34790036)
Int J Cell Biol. 2016;2016:6940283. (PMID: 27516776)
Circulation. 2006 May 2;113(17):2105-12. (PMID: 16636173)
Dis Markers. 2019 May 02;2019:3652894. (PMID: 31191749)
Indian J Psychol Med. 2013 Apr;35(2):121-6. (PMID: 24049221)
Aging Dis. 2014 Oct 01;5(5):294-306. (PMID: 25276489)
Front Neurol. 2020 Jun 10;11:384. (PMID: 32587562)
Front Nutr. 2023 Mar 17;10:1070808. (PMID: 37006940)
Front Immunol. 2022 Apr 01;13:688619. (PMID: 35432368)
Curr Opin Clin Nutr Metab Care. 2008 Jan;11(1):7-12. (PMID: 18090651)
Front Immunol. 2022 Jan 31;13:828447. (PMID: 35173738)
Int J Stroke. 2016 Jan;11(1):93-102. (PMID: 26763025)
Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):541-7. (PMID: 20657280)
Fam Med Community Health. 2020 Feb 16;8(1):e000262. (PMID: 32148735)
Clin Interv Aging. 2020 Mar 23;15:469-484. (PMID: 32273689)
Cell Transplant. 2019 Jul;28(7):864-873. (PMID: 31066288)
Int J Mol Sci. 2020 Sep 04;21(18):. (PMID: 32899616)
J Stroke Cerebrovasc Dis. 2020 May;29(5):104760. (PMID: 32173224)
PLoS Med. 2006 Nov;3(11):e442. (PMID: 17132052)
Nutrients. 2022 Oct 17;14(20):. (PMID: 36297037)
J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1555-63. (PMID: 26009498)
Immunology. 2018 Jul;154(3):363-376. (PMID: 29494762)
Front Immunol. 2023 Jan 05;13:1080737. (PMID: 36685518)
BMJ. 2015 Oct 28;351:h5527. (PMID: 26511519)

1406-16-2 (Vitamin D)
0 (Biomarkers)
0 (Cytokines)
207137-56-2 (Interleukin-4)
82115-62-6 (Interferon-gamma)

Date Created: 20240613 Date Completed: 20240613 Latest Revision: 20240615

20240615

PMC11175438

10.1371/journal.pone.0299631

38870172